Market closed · Next open: Monday 9:30 AM ET
Last update: Jul 31, 2026, 6:33 PM ET
Merck & Co., Inc.
$130.22 0.33% today
Market Closed

Why Merck & Co., Inc. (MRK) stock moved

Updated Aug 2, 2026

Merck & Co., Inc. (MRK) shares rose 0.3% to $130.22 as of August 2, 2026, a slight gain from the prior close of $129.79. BestStocks flagged the session as a major change for MRK. The move is tied to price move down. Below, we break down what changed for MRK, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

MRK climbed 0.3% to $130.22

MRK rose 0.3% in its latest session, moving from $129.79 to $130.22.

Material / EarningsSector-Wide MoveLow confidence
Rel. volume
0.5×
Below Avg
Vs peers
Top 2 of 7 peers
Outperforming
Market cap
$321.6B
New York Stock Exchange
Analyst target
$140
+7.2% vs price
Price chart
Not enough price data.
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Merck & Co., Inc. investors

For Merck & Co., Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Positive 0.3% session move. Weighing against that: Merck & Co., Inc. (MRK) moved -2.62% from $124.03 to $120.78 on 2026-07-14; MRK fell 2.68% to $125.06 on below-average volume (0.42x expected for this time of day). Because peers moved similarly, the shift looks more macro- or sector-driven than a change in MRK's fundamentals. Wall Street's consensus price target sits at $139.58, implying +7.2% upside from $130.22. BestStocks rates the overall signal quality low (40/100). With earnings roughly 2 days out, the next report is the most likely near-term test of the move.

MRK price reaction

MRK last traded at $130.22, up $0.43 (+0.33%) from the previous close of $129.79. The session traded on 0.5× average volume (below avg), so participation was unremarkable. Its healthcare peer group moved a median -0.6% over the same stretch, leaving MRK ahead of the group by 0.9 points.

Bullish and bearish analyst opinions on Merck & Co., Inc. (MRK)

The consensus analyst price target on Merck & Co., Inc. (MRK) is $139.58, 7.2% above the recent $130.22. Over the past 90 days analysts logged 0 upgrades, 10 maintains, and 0 downgrades. Here is how the bullish and bearish cases on MRK line up.

The bullish case

  • Wall Street's consensus price target of $139.58 implies +7.2% upside from $130.22.
  • The Street's most bullish target is $155.00 (+19.0%).
  • Material positive event.
  • Positive 0.3% session move.
  • Merck & Co., Inc. (MRK) moved +3.25% from $123.61 to $127.63 on 2026-07-16.

The bearish case

  • The most bearish analyst target is $105.00 (-19.4%).
  • Merck & Co., Inc. (MRK) moved -2.62% from $124.03 to $120.78 on 2026-07-14.
  • MRK fell 2.68% to $125.06 on below-average volume (0.42x expected for this time of day).
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Aug 2, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $140+7.2%
= 10 maintains
Barclays maintained Overweight · 2026-07-29
SEC filings watch
No recent filings
Peer context
MRK+0.3%
LLY-0.6%
UNH-1.7%
JNJ+0.2%
PFE+0.4%
ABBV-2.5%

Previous notable changes for MRK

Valuation2026-07-28via Yahoo Finance
Merck gained 2.88% to $134.53 following positive clinical trial results for Keytruda in endometrial cancer and expanded access initiatives, according to Yahoo Finance. The company's flagship oncology drug beat chemotherapy in a pivotal Phase 3 trial, while strategic moves to expand HIV PrEP access and advance an oral cholesterol drug pipeline boosted investor sentiment. Volume of 1.63M shares was 1.10x the time-adjusted historical average.
Material / Earnings2026-07-24
MRK moved -0.28% from its $131.44 open to a $131.07 close on 2026-07-24.
Valuation2026-07-23via ca.finance.yahoo.com
Merck gained 2.64% to $130.83, driven by strong sector performance and bullish analyst sentiment anchored in recent pipeline wins and label expansions. JP Morgan and other major firms raised price targets, citing positive Phase 3 data for immunology candidate tulisokibart and continued FDA label expansions for the oncology blockbuster Keytruda (sources: WSJ, Yahoo Finance). Volume at 0.78x expected is normal for this early trading window.
Activity2026-07-16
Merck & Co., Inc. (MRK) moved +3.25% from $123.61 to $127.63 on 2026-07-16. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move appears to be part of a sector-wide advance: five pharma and biotech peers (AMGN +4.60%, ABBV +3.93%, PFE +3.67%, BMY +6.25%) moved in the same direction on the same day, with volume 1.6x the 5-day average.
Upcoming catalysts & outlook
Next earnings
2026-08-04 (est.)
in 2 days
Earnings Release
2026-10-29
High impact
Thesis shift
Neutral / Mixed
bullish signal
Risk level
High
from change events

Frequently asked questions about MRK

Why did Merck & Co., Inc. (MRK) stock move?

MRK rose 0.3% to $130.22. No single company-specific catalyst was confirmed during the move window, and it looks like a sector-wide move.

How much did MRK stock rise?

MRK gained 0.33% ($0.43) versus the prior close of $129.79, last trading at $130.22 on 0.5× average volume.

When is Merck & Co., Inc.'s next earnings date?

MRK's next earnings report is estimated for 2026-08-04 — about 2 days away.

What is the analyst price target for MRK?

The consensus analyst price target for MRK is $139.58, about 7.2% above the current $130.22. Over the past 90 days, analysts recorded 0 upgrades, 10 maintains, and 0 downgrades.

Is the MRK move company-specific or sector-wide?

BestStocks classifies it as a sector-wide move: the peer group moved a median -0.6% against MRK's +0.3%. MRK ranks top 2 of 7 peers.

How BestStocks tracks MRK

This page is generated automatically by BestStocks' change-detection system after price move down was detected and verified against independent data sources. It draws on 14 tracked change events for MRK, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 2, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataSEC EDGAR filingsFMP earnings & estimatesAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.